CVRX Share Price Performance
US$7.48
1.00 (15.43%)
24.7% overvalued intrinsic discount
US$6.00
Fair Value
Price US$7.48
AnalystLowTarget US$6.00
AnalystConsensusTarget US$10.87
AnalystHighTarget US$14.00
Fair ValueUS$6.00
Share Pricen/a
CVRx, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
CVRX Community Narratives
AN
Fair Value US$6 24.7% overvalued intrinsic discount
Reimbursement Cuts Will Hinder Prospects Even As Device Uptake Persists
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$10.83 31.0% undervalued intrinsic discount
CPT Code Change Will Expand Heart Failure Treatment Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$14 46.6% undervalued intrinsic discount
Aging Population And Chronic Diseases Will Boost Heart Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Reimbursement Cuts Will Hinder Prospects Even As Device Uptake Persists
Key Takeaways Reimbursement cuts, economic headwinds, and slow adoption are set to limit revenue growth and keep the company unprofitable for an extended period. Narrow product indications and rising competition from alternative technologies threaten market share and further constrain long-term growth potential.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6
24.7% overvalued intrinsic discount
Fair Value
Profit Margin
13.08%
Future PE
17.86x
Price in 2029
US$7.57
Aging Population And Chronic Diseases Will Boost Heart Therapy Adoption
Key Takeaways Accelerated account expansion, effective talent strategies, and disease trends position CVRx for growth exceeding current forecasts and analyst expectations. Advancements in technology, digital integration, and global reach could significantly enhance both revenue quality and longer-term profitability.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14
46.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.32%
Future PE
44.82x
Price in 2028
US$17.58
CPT Code Change Will Expand Heart Failure Treatment Adoption
Key Takeaways Upcoming reimbursement improvements and expanded clinical evidence are set to boost physician adoption, leading to higher procedure volumes and increased revenue leverage. Strategic sales force expansion and targeted education will drive sustained demand, better market penetration, and enhanced long-term profitability.Read more
33
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$10.83
31.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.49%
Future PE
36.08x
Price in 2028
US$13.35
Trending Discussion
Recently Updated Narratives
AN
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Fair Value: US$6 24.7% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Chronic Diseases Will Boost Heart Therapy Adoption
Fair Value: US$14 46.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CPT Code Change Will Expand Heart Failure Treatment Adoption
Fair Value: US$10.83 31.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CVRx, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -2.03
- 85.33%
- -94.10%
- 125.9%
About CVRX
- Founded
- 2000
- Employees
- 223
- CEO
- WebsiteView website
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
